Literature DB >> 20198330

The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells.

Soo-A Kim1, Seong-Min Kwon, Jung-Hoon Yoon, Sang-Gun Ahn.   

Abstract

High levels of mitotic progression-associated PLK1 and stress-associated HSF1 have been observed in various human cancers. In the present study, we investigated the effects of PLK1 and HSF1 knockdown on the proliferation of oral cancer cells using small interfering RNA. In human oral squamous cell carcinoma (SCC) tissues, the levels of PLK1 and HSF1 were higher compared to normal tissues. The expression levels of PLK1 and HSF1 were also elevated in the human oral SCC cell lines FaDu and HEp-2. Disruption of PLK1 induced cell cycle arrest at G2/M phase as well as apoptosis in oral cancer cells. Interestingly, knockdown of both PLK1 and HSF1 expression decreased cell proliferation while increasing apoptotic cell death in synergistic fashion. These results establish the potential value of PLK1 and HSF1 as targets for oral cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20198330     DOI: 10.3892/ijo_00000564

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo.

Authors:  Phan L C H B Tran; Soo-A Kim; Hong Seok Choi; Jung-Hoon Yoon; Sang-Gun Ahn
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

Review 2.  HSF1: Guardian of Proteostasis in Cancer.

Authors:  Chengkai Dai; Stephen Byers Sampson
Journal:  Trends Cell Biol       Date:  2015-11-18       Impact factor: 20.808

Review 3.  HSF1 as a Cancer Biomarker and Therapeutic Target.

Authors:  Richard L Carpenter; Yesim Gökmen-Polar
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

Review 4.  PLK1, A Potential Target for Cancer Therapy.

Authors:  Zhixian Liu; Qingrong Sun; Xiaosheng Wang
Journal:  Transl Oncol       Date:  2016-11-24       Impact factor: 4.243

5.  Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA.

Authors:  Yoshiyuki Hattori; Takuto Kikuchi; Kei-Ichi Ozaki; Hiraku Onishi
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

6.  A study on the biological function of heat shock factor 1 proteins in breast cancer.

Authors:  Xiaolan Wang; Dianlong Zhang; Mingqian Cao; Jinling Ba; Bin Wu; Tao Liu; Chen Nie
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

7.  Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition.

Authors:  Rui Song; Ge Hou; Jun Yang; Jinjin Yuan; Cheng Wang; Ting Chai; Zongwen Liu
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

8.  BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.

Authors:  Guodong Lian; Leping Li; Yulong Shi; Changqing Jing; Jinglei Liu; Xiaobo Guo; Qingqing Zhang; Tianyu Dai; Fei Ye; Yanyan Wang; Man Chen
Journal:  Int J Oncol       Date:  2018-01-25       Impact factor: 5.650

9.  Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma.

Authors:  M Lupu-Plesu; A Claren; S Martial; P-D N'Diaye; K Lebrigand; N Pons; D Ambrosetti; I Peyrottes; J Feuillade; J Hérault; M Dufies; J Doyen; G Pagès
Journal:  Oncogenesis       Date:  2017-07-03       Impact factor: 7.485

10.  SKA3 Promotes Cell Growth in Breast Cancer by Inhibiting PLK-1 Protein Degradation.

Authors:  Li-Wei Ruan; Peng-Peng Li; Lang-Ping Jin
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.